Centessa (CNTA) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
0
Operating Income
-201.1M
Net Income
-235.8M
EPS (Diluted)
-$2.06
Balance Sheet Metrics
Total Assets
576.8M
Total Liabilities
175.3M
Shareholders Equity
401.5M
Debt to Equity
0.44
Cash Flow Metrics
Operating Cash Flow
-209.4M
Free Cash Flow
-142.1M
Revenue & Profitability Trend
Centessa Income Statement From 2019 to 2024
| Metric | 2024 | 2023 | 2022 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 6.9M | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 201.1M | 178.1M | 210.3M | 10.4M | 5.1M |
| Operating Income | -201.1M | -171.3M | -210.3M | -10.4M | -5.1M |
| Pre-tax Income | -232.9M | -176.1M | -217.0M | -10.7M | -5.1M |
| Income Tax | 2.8M | -25.1M | -747.0K | - | - |
| Net Income | -235.8M | -151.1M | -216.2M | -10.7M | -5.1M |
| EPS (Diluted) | -$2.06 | -$1.57 | -$2.31 | -$0.15 | -$0.07 |
Income Statement Trend
Centessa Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 536.4M | 315.1M | 437.7M | 628.8M | 11.2M |
| Non-Current Assets | 40.4M | 45.2M | 6.6M | 861.0K | 552.0K |
| Total Assets | 576.8M | 360.2M | 444.3M | 629.6M | 11.7M |
| Liabilities | |||||
| Current Liabilities | 58.0M | 39.4M | 38.3M | 24.6M | 8.6M |
| Non-Current Liabilities | 117.3M | 84.6M | 69.8M | 113.4M | 25.5M |
| Total Liabilities | 175.3M | 124.0M | 108.1M | 138.1M | 34.1M |
| Equity | |||||
| Total Shareholders Equity | 401.5M | 236.2M | 336.2M | 491.6M | -22.4M |
Balance Sheet Composition
Centessa Cash Flow Statement From 2019 to 2024
| Metric | 2024 | 2023 | 2022 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -235.8M | -151.1M | -216.2M | -10.7M | -5.1M |
| Operating Cash Flow | -209.4M | -164.1M | -199.2M | -11.8M | -4.6M |
| Investing Activities | |||||
| Capital Expenditures | -34.0K | -169.0K | -1.1M | 0 | 0 |
| Investing Cash Flow | 31.3M | -127.0M | -931.0K | 0 | 0 |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 353.5M | 20.8M | -261.0K | 1.4M | 9.0M |
| Free Cash Flow | -142.1M | -160.5M | -201.7M | -10.6M | -5.8M |
Cash Flow Trend
Centessa Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-6.81
Forward P/E
-7.96
Price to Book
4.71
Price to Sales
125.33
PEG Ratio
-7.96
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-205.18%
Return on Equity
-74.44%
Return on Assets
-28.58%
Financial Health
Current Ratio
14.37
Debt to Equity
30.55
Beta
1.49
Per Share Data
EPS (TTM)
-$1.82
Book Value per Share
$2.89
Revenue per Share
$0.12
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| cnta | 1.9B | -6.81 | 4.71 | -74.44% | 0.00% | 30.55 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Vera Therapeutics | 1.4B | -8.41 | 2.58 | -39.49% | 0.00% | 10.18 |
| Immunocore Holdings | 1.6B | -31.41 | 4.13 | -5.86% | -6.48% | 114.67 |
| Agios | 2.1B | 3.17 | 1.44 | 60.26% | 1,798.26% | 3.61 |
Financial data is updated regularly. All figures are in the company's reporting currency.